{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:01:53Z","timestamp":1789614113075,"version":"build-2803163510"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>\n                    Drug repurposing represents a pragmatic strategy for patients with cancer who have limited standard-of-care options. Traditional\n                    <jats:italic>in silico<\/jats:italic>\n                    or functional repurposing approaches often rely on well-characterised protein targets or validated experimental models, which are sparsely available in rare cancer settings and impractical within clinically relevant timeframes. Tumour-agnostic biomarker-driven strategies, by contrast, offer more timely workflows for integration into routine oncology practice, but have largely been dominated by \u2018on-target\u2019 approaches that may be less applicable to rare cancers frequently lacking canonical targetable mutations. However, emerging pharmacological evidence demonstrates that many anticancer agents engage a broader target landscape, creating opportunities for \u2018off-target\u2019 repurposing against non-canonical tumour dependencies. Although less established, we contend \u2018off-target\u2019 repurposing remains a potentially important strategy offering therapeutic hope to patients with rare cancers for whom no standard options, targetable biomarkers, or disease-specific trials exist. This perspective explores emerging evidence surrounding \u2018off-target\u2019 repurposing as a strategy, as well as evaluating recent criticisms of off-target low-evidence genomic matching in precision oncology literature. By doing so, we advocate for development of rigorously designed prospective clinical trials to examine \u2018off target\u2019 strategies, centred in safety of participants, evidence generation, and accessibility. Such frameworks require embedding off-target candidates within trial designs suited to small heterogeneous cohorts, with built-in mechanisms for evidence generation and access to therapies. We propose safe implementation should incorporate longitudinal monitoring, and parallel orthogonal validation to strengthen biological and pharmacological plausibility, refine drug and dose selection, and inform adaptive treatment modification over time.\n                  <\/jats:p>","DOI":"10.3389\/fgene.2026.1921857","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:04:26Z","timestamp":1789610666000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Off-target drug repurposing for rare and ultra-rare cancers: towards a scalable therapeutic framework"],"prefix":"10.3389","volume":"17","author":[{"given":"Gehan","family":"Premaratne","sequence":"first","affiliation":[{"name":"Alfred Hospital","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaka","family":"Ameratunga","sequence":"additional","affiliation":[{"name":"Alfred Hospital","place":["Melbourne, VIC, Australia"]},{"name":"Department of Cancer Medicine, Monash University","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/bjc.2017.321","article-title":"Rare cancers: the greatest inequality in cancer research and oncology treatment","volume":"117","author":"Alvi","year":"2017","journal-title":"Br. J. Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.chembiol.2017.11.004","article-title":"Objective, quantitative, data-driven assessment of chemical probes","volume":"25","author":"Antolin","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1038\/s41598-020-59074-4","article-title":"The kinase polypharmacology landscape of clinical PARP inhibitors","volume":"10","author":"Antolin","year":"2020","journal-title":"Sci. Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","article-title":"Prioritization of cancer therapeutic targets using CRISPR\u2013Cas9 screens","volume":"568","author":"Behan","year":"2019","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1400029","DOI":"10.3389\/fphar.2024.1400029","article-title":"In silico approaches for drug repurposing in oncology: a scoping review","volume":"15","author":"Cavalcante","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41698-025-00851-7","article-title":"Functional combinatorial precision medicine for predicting and optimizing soft tissue sarcoma treatments","volume":"9","author":"Chan","year":"2025","journal-title":"Npj Precis. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","article-title":"Discovering the anticancer potential of non-oncology drugs by systematic viability profiling","volume":"1","author":"Corsello","year":"2020","journal-title":"Nat. Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejca.2022.03.001","article-title":"The gap between rare and common cancers still exists: results from a population-based study in the Netherlands","volume":"167","author":"De Heus","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJMc1013224","article-title":"Crizotinib in Anaplastic large-cell lymphoma","volume":"364","author":"Gambacorti-Passerini","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"eabn7824","DOI":"10.1126\/scitranslmed.abn7824","article-title":"An ex vivo platform to guide drug combination treatment in relapsed\/refractory lymphoma","volume":"14","author":"Goh","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1158\/1078-0432.CCR-21-3752","article-title":"Patients with rare cancers in the drug rediscovery protocol (DRUP) benefit from genomics-guided treatment","volume":"28","author":"Hoes","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"eaan4368","DOI":"10.1126\/science.aan4368","article-title":"The target landscape of clinical kinase drugs","volume":"358","author":"Klaeger","year":"2017","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","article-title":"Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders","volume":"12","author":"Kornauth","year":"2022","journal-title":"Cancer Discov."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.4389","article-title":"Functional precision cancer medicine\u2014moving beyond pure genomics","volume":"23","author":"Letai","year":"2017","journal-title":"Nat. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","article-title":"Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations","volume":"40","author":"Letai","year":"2022","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41698-021-00194-z","article-title":"Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology","volume":"5","author":"Lin","year":"2021","journal-title":"Npj Precis. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/jamaoncol.2026.0127","article-title":"Genomic therapy matching in rare and refractory cancers","volume":"12","author":"Lin","year":"2026","journal-title":"JAMA Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1001\/jamaoncol.2018.0723","article-title":"Targetable alterations in adult patients with soft-tissue sarcomas: insights for personalized therapy","volume":"4","author":"Lucchesi","year":"2018","journal-title":"JAMA Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","article-title":"Implementing a functional precision medicine Tumor Board for Acute Myeloid leukemia","volume":"12","author":"Malani","year":"2022","journal-title":"Cancer Discov."},{"key":"B20","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children\u2019s Oncology Group phase 1 consortium study","volume":"14","author":"Moss\u00e9","year":"2013","journal-title":"Lancet Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"29","author":"O\u2019Dwyer","year":"2023","journal-title":"Nat. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.semcancer.2020.02.003","article-title":"Turning liabilities into opportunities: Off-target based drug repurposing in cancer","volume":"68","author":"Palve","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.12793\/tcp.2019.27.2.59","article-title":"A review of computational drug repurposing","volume":"27","author":"Park","year":"2019","journal-title":"Transl. Clin. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","article-title":"Cancer biomarkers: emerging trends and clinical implications for personalized treatment","volume":"187","author":"Passaro","year":"2024","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature14119","article-title":"Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation","volume":"519","author":"Pemovska","year":"2015","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s42003-019-0305-x","article-title":"A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids","volume":"2","author":"Phan","year":"2019","journal-title":"Commun. Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B29","doi-asserted-by":"publisher","first-page":"eaan0941","DOI":"10.1126\/scitranslmed.aan0941","article-title":"Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP)","volume":"10","author":"Rashid","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"104390","DOI":"10.1016\/j.drudis.2025.104390","article-title":"Therapeutic innovation in drug repurposing: challenges and opportunities","volume":"30","author":"Recino","year":"2025","journal-title":"Drug Discov. Today"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1 -Rearranged Non\u2013Small-Cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK -Positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/humu.22225","article-title":"Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden markov models","volume":"34","author":"Shihab","year":"2013","journal-title":"Hum. Mutat."},{"key":"B34","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO-25-01453","article-title":"Investigation of profile-related evidence determining individualized cancer therapy (I-PREDICT) N-of-1 precision oncology Study: molecular profiling to match individually dosed, personalized drug combinations","volume":"44","author":"Sicklick","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1016\/S2352-3026(17)30208-9","article-title":"Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study","volume":"4","author":"Snijder","year":"2017","journal-title":"Lancet Haematol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1002\/cncr.33618","article-title":"Ultra\u2010rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities","volume":"127","author":"Stacchiotti","year":"2021","journal-title":"Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"114003","DOI":"10.1016\/j.ejca.2024.114003","article-title":"How to develop new systemic treatments in ultra-rare cancers with high unmet needs? The case of alveolar soft-part sarcoma","volume":"202","author":"Stacchiotti","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e100051","DOI":"10.1200\/EDBK-25-100051","article-title":"Designing clinical trials for patients with rare cancers: connecting the zebras","volume":"45","author":"Subbiah","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"B40","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41573-025-01164-x","article-title":"Computational drug repurposing: approaches, evaluation of in silico resources and case studies","volume":"24","author":"Tanoli","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"B41","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"B42","unstructured":"Table of pharmacogenomic biomarkers in drug labeling\n          \n          \n          2026"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/s41591-026-04280-2","article-title":"Real-world clinical utility of tumor whole-genome sequencing in solid cancers","volume":"32","author":"Van Putten","year":"2026","journal-title":"Nat. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41571-023-00745-2","article-title":"Functional precision oncology using patient-derived assays: bridging genotype and phenotype","volume":"20","author":"Van Renterghem","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/annonc\/mdz119","article-title":"Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients","volume":"30","author":"Van Waalwijk Van Doorn-Khosrovani","year":"2019","journal-title":"Ann. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-026-10405-x","article-title":"Prospective evaluation of genomics-guided off-label treatment","volume":"653","author":"Verkerk","year":"2026","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5644\/ama2006-124.392","article-title":"Tumor-Type agnostic, targeted therapies: BRAF Inhibitors Join the Group","volume":"51","author":"Vranic","year":"2023","journal-title":"Acta Medica Acad."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e1657","DOI":"10.1002\/ctm2.1657","article-title":"Computational repurposing of oncology drugs through off\u2010target drug binding interactions from pharmacological databases","volume":"14","author":"Walpole","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1017\/erm.2022.32","article-title":"Precision oncology using ex vivo technology: a step towards individualised cancer care?","volume":"24","author":"Williams","year":"2022","journal-title":"Expert Rev. Mol. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for cancer therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct. Target Ther."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1921857\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:04:27Z","timestamp":1789610667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1921857\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":50,"alternative-id":["10.3389\/fgene.2026.1921857"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2026.1921857","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1921857"}}